Skip to content
10-Q

Quarterly Report

RETINALGENIX TECHNOLOGIES INC. RTGN

0001493152-24-046477

← back to feed
Filed
Nov 18, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 12, 2024 18.09M sh
Current Liabilities Q3 2024 · Sep 30, 2024 $1.94M
Current Liabilities Q3 2024 · Dec 31, 2023 $1.41M
Total Liabilities Q3 2024 · Sep 30, 2024 $1.94M
Total Liabilities Q3 2024 · Dec 31, 2023 $1.41M
Current Assets Q3 2024 · Sep 30, 2024 $79.09K
Total Assets Q3 2024 · Sep 30, 2024 $88.85K
Total Assets Q3 2024 · Dec 31, 2023 $156
Shares Diluted Q3 2024 · Sep 30, 2023 17.28M sh
Shares Diluted Q3 2024 · Sep 30, 2023 17.27M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$161.64K
Stockholders Equity restated Q3 2024 · Sep 30, 2023 −$1.08M
Stockholders Equity Q3 2024 · Jun 30, 2023 −$1.77M
Stockholders Equity Q3 2024 · Mar 31, 2023 −$1.5M
Stockholders Equity Q3 2024 · Dec 31, 2022 −$1.07M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.04
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.09
Eps Basic Q3 2024 · Sep 30, 2023 −$0.04
Eps Basic Q3 2024 · Sep 30, 2023 −$0.09
Sga Expense Q3 2024 · Sep 30, 2023 $167.05K
Sga Expense Q3 2024 · Sep 30, 2023 $490.39K
Net Income Q3 2024 · Sep 30, 2023 −$686.47K
Net Income Q3 2024 · Sep 30, 2023 −$1.55M
Net Income Q3 2024 · Jun 30, 2023 −$352.14K
Net Income Q3 2024 · Mar 31, 2023 −$510.64K